Laboratory Co. of America (LH) Projected to Post Quarterly Earnings on Thursday

Laboratory Co. of America (NYSE:LH) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect Laboratory Co. of America to post earnings of $3.40 per share and revenue of $3.31 billion for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Laboratory Co. of America Stock Down 0.9 %

LH opened at $246.36 on Thursday. The firm’s 50 day simple moving average is $235.43 and its two-hundred day simple moving average is $227.96. The company has a market capitalization of $20.61 billion, a PE ratio of 47.65, a PEG ratio of 1.81 and a beta of 1.06. Laboratory Co. of America has a 1-year low of $191.97 and a 1-year high of $250.56. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66.

Laboratory Co. of America Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be issued a $0.72 dividend. The ex-dividend date is Thursday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

Analyst Upgrades and Downgrades

A number of analysts have commented on LH shares. HSBC upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Evercore ISI upgraded shares of Laboratory Co. of America from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $260.00 to $265.00 in a research note on Tuesday, January 7th. StockNews.com lowered shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Bank of America raised their price objective on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Finally, Barclays upped their target price on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a report on Friday, October 25th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Laboratory Co. of America has a consensus rating of “Moderate Buy” and a consensus target price of $261.77.

Insider Buying and Selling

In other news, Director Kerrii B. Anderson sold 1,000 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $235,000.00. Following the sale, the director now directly owns 12,722 shares in the company, valued at $2,989,670. The trade was a 7.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Glenn A. Eisenberg sold 11,711 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $240.43, for a total transaction of $2,815,675.73. Following the completion of the transaction, the executive vice president now directly owns 31,289 shares of the company’s stock, valued at approximately $7,522,814.27. The trade was a 27.23 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,572 shares of company stock worth $5,915,209. Corporate insiders own 0.85% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.